Ruxolitinib dosing for acute graft-versus-host disease in a pediatric patient receiving continuous renal replacement therapy

Pediatr Blood Cancer. 2024 Jan;71(1):e30754. doi: 10.1002/pbc.30754. Epub 2023 Oct 30.

Authors

Teaghan T Chen¹, Alexandria P David¹, Sharon E Gordon¹, Laura McLaughlin^{1

2}

Affiliations

¹ Department of Pharmacy Aurora CO, Children's Hospital Colorado, Aurora, Colorado, USA.
² Department of Pediatrics, Section of Hematology/Oncology and Bone Marrow Transplantation, University of Colorado School of Medicine, Aurora, Colorado, USA.

PMID: 37899702
DOI: 10.1002/pbc.30754

No abstract available

Publication types

Letter

MeSH terms

Acute Disease
Child
Continuous Renal Replacement Therapy*
Graft vs Host Disease* / drug therapy
Graft vs Host Disease* / etiology
Hematopoietic Stem Cell Transplantation*
Humans
Nitriles
Pyrimidines
Retrospective Studies

Substances

ruxolitinib
Nitriles
Pyrimidines